AUS
NZ
UK
CA
USA
IND
Healthcare
Nebulised R327 Shows Strong Pneumonia Response: ASX 200 Treatment Insights
November 26, 2025 06:59 PM AEDT| By SamInhaled R327 research highlights the expanding influence of synthetic anti-infective science in Australia, reinforcing interest in respiratory therapies, hospital-focused delivery systems and evolving infection-control pathways.
Recce Pharma’s Inhaled R327 Advances Drug-Resistant Pneumonia
November 26, 2025 06:30 PM AEDT| By Team Kalkine MediaRecce Pharmaceuticals (ASX:RCE) reports strong preclinical results for inhaled R327 against multidrug-resistant pneumonia, highlighting innovative delivery and broad-spectrum activity.
4DMedical Ltd Quotation Sparks ASX 200 Market Interest
November 26, 2025 05:50 PM AEDT| By Sam4DMedical Ltd lists new securities on ASX, enhancing its market presence, driving sector engagement, and influencing ASX 200 activity across medical technology and investor-focused segments.
Race Oncology Gains Ethics Nod for Lung Cancer RC220 Study
November 26, 2025 05:36 PM AEDT| By Team Kalkine MediaRace Oncology (ASX:RAC) has received ethical approval to progress its RC220 treatment into an early-stage study for a specific type of lung cancer. This article explores how the therapy will be tested,
Pro Medicus Stock Insights: ASX 200 Performance & Market Trends
November 26, 2025 03:35 PM AEDT| By SamPro Medicus (ASX:PME) shows strong growth through US contracts and healthcare innovation, remaining resilient in a volatile ASX 200 and highlighting technology sector potential in Australia.
SECTOR SURGE: ASX Momentum Builds Amid Inflation Heat
November 26, 2025 03:03 PM AEDT| By SamThe market rose steadily despite inflation pressure, supported by healthcare strength, sustainable agriculture interest, resource exploration progress and innovative energy developments. Sector interplay offered a balanced tone across the session.
Race Oncology Launches HARNESS-1 Lung Cancer Trial RC220
November 26, 2025 01:27 PM AEDT| By Team Kalkine MediaRace Oncology Ltd (ASX:RAC) receives ethics approval for its HARNESS-1 Phase 1a/b lung cancer trial of RC220 with osimertinib. The multi-centre study will evaluate safety, tolerability, and pharmacokinetics, aiming to provide new insights into NSCLC...
Is Sonic Healthcare Ltd (ASX:SHL) a Key Player for Investors in 2025?
November 25, 2025 05:30 PM AEDT| By Team Kalkine MediaExplore Sonic Healthcare Ltd (ASX:SHL) and its market performance in 2025. Discover revenue trends, financial health, and operational metrics while examining how it positions itself in the broader ASX stock market.
Ramsay’s Hospital Revival Gains Pace Across the ASX 200
November 25, 2025 04:00 PM AEDT| By SamRamsay Health Care’s improved early-year performance signals renewed strength within Australia’s private hospital sector, supported by steadier patient activity, refined capital direction and more balanced operational momentum across major facilities...
Cann Group (ASX:CAN) Announces Quotation of New Securities on ASX
November 24, 2025 01:08 PM AEDT| By SamCann Group (ASX:CAN) announces the quotation of new securities to enhance liquidity, support growth, and strengthen shareholder engagement in the medicinal cannabis sector.
Monash IVF Rebuffs Bid as ASX 200 Spotlight Intensifies
November 24, 2025 11:17 AM AEDT| By SamMonash IVF’s rejection of a takeover proposal has intensified attention across the ASX landscape, highlighting sector strength, company positioning, and broader interest in healthcare operators during shifting market conditions.
SHG Strengthens Industry Presence While All Ordinaries Momentum Expands Around Singular Health Group
November 21, 2025 05:41 PM AEDT| By Team Kalkine MediaSingular Health Group receives renewed attention as digital healthcare modelling, operational discussions, and sector-wide innovation continue shaping its presence within medical technology.
Sonic Healthcare Expands Operational Impact as ASX 100 Momentum Shapes SHL
November 21, 2025 04:11 PM AEDT| By SamSonic Healthcare draws heightened visibility as reported, operational adjustments, and diagnostic service trends continue to shape its presence within the healthcare sector.
Singular Health Group Advances as All Ordinaries Momentum Builds Around SHG
November 21, 2025 03:52 PM AEDT| By SamSingular Health Group continues to attention as its digital healthcare innovations, operational developments, and public commentary shape its presence within the Australian medical technology sector.
CSL Ltd ASX 20 Transformation Moves Into New Phase With Major Global Expansion
November 21, 2025 03:12 PM AEDT| By Team Kalkine MediaCSL advances through a major transformation involving structural refinement, operational alignment and division-specific reorganisation within its global healthcare framework.
Singular Health Group (ASX:SHG) Maintains Strong Cash Runway for Growth
November 21, 2025 12:25 PM AEDT| By Team Kalkine MediaSingular Health Group maintains strong cash reserves, low debt, and strategic growth initiatives, positioning it well within the ASX 200 healthcare sector during periods of market volatility.
MedAdvisor (ASX:MDR) Revenue Struggles Limit ASX 200 Stock Prospects
November 21, 2025 11:48 AM AEDT| By SamMedAdvisor Limited (ASX:MDR) has low revenue growth and a modest P/S ratio. ASX 200 investors monitor performance relative to peers as the company works to improve its market outlook.
CSL Expansion Boosts US Operations: ASX Shares and Market Update
November 21, 2025 11:24 AM AEDT| By SamCSL (ASX:CSL) plans a $1.5 billion US expansion to boost immunoglobulin supply and manufacturing, with a focus on biologics, gene therapies, and operational efficiency amid market volatility.
Sonic Healthcare Faces Fresh Valuation Debate After Market Pullback
November 20, 2025 12:48 PM AEDT| By SamSonic Healthcare’s valuation draws renewed scrutiny as market conditions shift, inviting deeper assessment of its long-term demand, sector fundamentals and evolving strategic context within global healthcare.
Is the Market Misreading NYR as ASX 200 Sentiment Shifts?
November 20, 2025 12:25 PM AEDT| By SamNyrada experiences softer sentiment as ownership dynamics, biotechnology challenges and broader market themes shape perceptions, highlighting the gap between long-term scientific development and short-term market reactions.
Advertise your brand on Kalkine Media